A multicenter open-label phase I/II study to assess the safety, tolerability, and efficacy of three dose levels of TuNEX in patients with rheumatoid arthritis  by Chen, Der-Yuan et al.
Available online at www.sciencedirect.comJournal of the Chinese Medical Association 74 (2011) 544e551
www.jcma-online.comOriginal Article
A multicenter open-label phase I/II study to assess the safety,
tolerability, and efficacy of three dose levels of TuNEX
in patients with rheumatoid arthritis
Der-Yuan Chen a,b,c, Ning-Sheng Lai d,e, Ling-Ying Lu f, Hsiu-Cheng Chou a,
Yi-Hsing Chen a,b, Tsu-Yi Hsieh a,c, Yi-Ming Chen a,b, Joung-Liang Lan a,b,c,*
aDivision of Allergy, Immunology, and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ROC
bFaculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC
c School of Medicine, Chung-Shan Medical University, Taichung, Taiwan, ROC
dDivision of Allergy, Immunology, and Rheumatology, Buddhist Dalin Tzu Chi Hospital, Chiayi, Taiwan, ROC
eCollege of Medicine, Tzu Chi University, Hualien, Taiwan, ROC
fDivision of Allergy, Immunology, and Rheumatology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC
Received October 15, 2010; accepted September 2, 2011AbstractBackground: Tumor necrosis factor (TNF)-a is a pivotal inflammatory cytokine in the pathogenesis of rheumatoid arthritis (RA). TuNEX,
a recombinant TNF-a receptor protein, can effectively bind TNF-a. The purpose of this phase I/II dose-escalation study was to assess the safety
and preliminary efficacy of three dose levels of TuNEX in Taiwanese patients with RA.
Methods: Eighteen patients with active RA from three medical centers who had failed previous therapy with at least one disease modifying
antirheumatic drug (DMARD) were enrolled. The primary efficacy endpoint was a 20% improvement in the American College of Rheumatology
criteria (ACR20) in the fourth week. The occurrence of treatment-emergent adverse events (TEAEs) was the primary safety variable.
Results: The highest percentage of TuNEX 25-mg- and 35-mg-treated patients achieved an ACR20 response (60% and 100%, respectively) for
the first time at Week 2 during the 4-week treatment period. There was a strong trend toward a superior ACR20 response rate in the TuNEX 15-
mg group (83.3%) in comparison with the TuNEX 25-mg group (40.0%) and the TuNEX 35-mg group (50.0%) at week 4. Patients who received
15-mg TuNEX, 25-mg TuNEX, and 35-mg TuNEX had 35.99%, 16.85%, and 21.86% reduction of disability indices of Health Assessment
Questionnaire after drug treatment, respectively. The most commonly reported adverse event was injection-site reaction. The TEAEs were
comparable between the three TuNEX-treated groups.
Conclusion: TuNEX reduced the signs and symptoms of RA and improved physical function, with clinically acceptable safety and tolerability in
patients who had previously received DMARDs.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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1. Introduction Although disease modifying antirheumatic drugs (DMARDs)Rheumatoid arthritis (RA), which is characterized by
a progressive inflammatory synovitis, should be treated early
and aggressively to prevent joint destruction and disability.1,2* Corresponding author. Dr. Joung-Liang Lan, Division of Allergy, Immu-
nology and Rheumatology, Taichung Veterans General Hospital, 160, Section
3, Taichung-Kang Road, Taichung 407, Taiwan, ROC.
E-mail address: jllan@vghtc.gov.tw (J.-L. Lan).
1726-4901/$ - see front matter Copyright  2011 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2011.10.009can inhibit disease progression, many patients fail to achieve
an adequate response to therapy due to lack of efficacy or
toxicity.3 Tumor necrosis factor (TNF)-a is a crucial inflam-
matory mediator in synovitis and subsequent tissue damage in
RA, and therefore represents a promising target for therapeutic
intervention in this disease.4e6 Clinical and pharmacologic
studies have shown that TNF-a inhibitors can be an effective
and well-tolerated therapy for patients with RA.7e10hinese Medical Association. All rights reserved.
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extracellular domain of the human 75-kilodalton (p75) TNF
receptor (TNFR) linked to the constant region of human
immunoglobulin (Ig) G1. The extracellular portion of TNFR
was also discovered as soluble TNF-a-binding protein in urine
and serum and plays a physiologic role by inhibiting TNF-a
activity. TuNEX is produced by recombinant DNA technology
in a Chinese hamster ovary mammalian cell expression system
and was developed by Mycenax Biotech Inc. (Miaoli County,
Taiwan). Since TNF-a is an important proinflammatory
cytokine in the pathogenesis of RA, it is hypothesized that
TuNEX might be useful in the treatment of this disease.
TuNEX consists of 934 amino acids, has an apparent molec-
ular weight of approximately 150 kilodaltons, and is a biologic
product similar to etanercept, which has been granted market
approval in Taiwan. Based on the conclusion of preclinical
(phase I) studies (13-week subcutaneous toxicity in cyn-
omolgus monkeys with a 4-week interim sacrifice and
a 4-week recovery phase) and the consideration of safety
margin in humans, the effective dose range for TuNEX has
been judged to be 15e35 mg given subcutaneously (sc) twice
weekly.
The present study is the first phase I/II clinical trial to
assess the safety and preliminary efficacy of three dose levels
of TuNEX in Taiwanese patients with RA. Patients with RA
with history of treatment failure with at least one of the
DMARDs received one of the following doses: (1) 15 mg
TuNEX given (sc) twice weekly, (2) 25 mg TuNEX given sc
twice weekly, or (3) 35 mg TuNEX given sc twice weekly.
Proportions of patients with dose-limiting toxicity (DLT) were
the primary outcome of the study. Efficacy, incidence of
adverse events, and immunogenicity were the secondary
outcomes planned in the study.
2. Methods2.1. PatientsThis multicenter study was conducted at Taichung Veterans
General Hospital, Kaohsiung Veterans General Hospital, and
Buddhist Dalin Tzu Chi Hospital in Taiwan. Twenty-seven
patients who fulfilled the American College of Rheuma-
tology (ACR) 1987 revised criteria for RA11 and had failed
previous therapy with at least one of the DMARDs were
enrolled at the time of screening. Treatment failure was
defined as either intolerance or discontinuation due to lack of
efficacy determined by investigator. DMARDs include meth-
otrexate, hydroxychloroquine, gold preparations, azathioprine,
D-penicillamine, sulfasalazine, and cyclosporine. Patients
receiving DMARDs at the time of screening were required to
undergo a washout for 4 weeks before start of study medica-
tion. Active disease at the time of screening was defined as six
or more swollen joints and six or more tender joints, and
presence of at least one of the following criteria: erythrocyte
sedimentation rate (ESR)  28 mm/h, C-reactive protein
(CRP)  2.0 mg/dL, and duration of morning stiffness for at
least 45 minutes.Patients were excluded if they had received any of the
following: biologic products (such as etanercept, infliximab,
and adalimumab) within 4 weeks prior to planned start of trial
treatment (Day 0), and/or exposure to anti-CD20 antibodies
within 2 years before screening for this trial; any use of
cyclophosphamide, nitrogen mustard, chlorambucil, or other
alkylating agents within 5 years before screening for this trial;
use of leflunomide12 weeks prior to planned start of trial
treatment (Day 0); intra-articular treatment with corticoste-
roids within 4 weeks before screening; or live vaccine within
3 months prior to study. Other criteria for exclusion were as
follows: past or current malignancy, except for resected
cervical carcinoma Stage 1B or less, resected noninvasive
basal cell and squamous cell skin carcinoma, malignant
melanoma with a complete response of a duration of >10
years, and other cancer diagnoses with a complete response of
a duration of >5 years; history of infected joint prosthesis
within 5 years before screening and infected native joints
within 1 year before screening; patients known or suspected to
be unable to comply with this trial protocol (such as due to
alcoholism, drug dependency, or psychological disorder);
patients with clinically active tuberculosis (TB) or radio-
graphic evidence of old pulmonary TB; patients with renal
impairment (serum creatinine >2.0 mg/dL) and hepatic
impairment (alanine aminotransferase, asparate transaminase
values >2 times the upper limit of normal range); patients
with laboratory test abnormality (blood chemistry or hema-
tology) that, in the investigator’s opinion, might put the patient
at a higher risk if treated with study medication; pregnant and
nursing mothers; patients with positive serology for human
immunodeficiency virus antibody, hepatitis B surface antigen
(HBsAg) or hepatitis C (HCV) antibody; history of another
collagen-vascular disease; preexisting or recent onset of
central nervous system demyelinating disorders; patients with
significant medical diseases, including uncompensated
congestive heart failure, severe myocardial infarction within 6
months, uncontrolled hypertension, poorly controlled diabetes
mellitus, and chronic or active infection; and patients with any
condition that might cause their participation in this study to
be detrimental, as judged by a physician. In addition,
concomitant use of DMARDs or any other investigational
drugs were prohibited during this study. However, stable doses
of oral corticosteroids ( 10 mg prednisone or equivalent),
nonsteroidal anti-inflammatory drugs were permitted, but the
dose could not be greater than the maximum level recom-
mended by the manufacturer. Patients could receive analgesics
during the study except for the 24-hour period before sched-
uled joint examination. This study was approved by the
Clinical Research Ethics Committee of Taichung Veterans
General Hospital, Kaohsiung Veterans General Hospital and
Buddhist Dalin Tzu Chi Hospital, and informed consent was
obtained from each participant.2.2. Study designThis was an open-labeled, nonrandomized, sequential dose-
escalating clinical exploratory study to assess the safety and
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Fig. 1, six patients with RA received the lowest dose level of
TuNEX 15 mg sc twice weekly at the start of the study (Arm
A). A safety review was conducted at the end treatment period
of Arm A. If less than one-third of patients in Arm A were
reported as DLT, the study continued to treat an additional six
patients with the medium dose levels of TuNEX 25 mg sc
twice weekly (Arm B). A safety review was conducted at the
end-treatment period of Arm B. If less than one-third of
patients in Arm B were reported as DLT, the study continued
to treat 6 more patients with the maximal dose level of TuNEX
35 mg sc twice weekly (Arm C).
The therapeutic response was defined according to the ACR
Response Criteria.12 Visual analogue scale (VAS) was used to
assess pain and global assessment. The Chinese version of
Health Assessment Questionnaire (HAQ)-Disability Index was
used to assess disability.13 Clinical and laboratory assessment
were performed before the start of treatment, 72 hours after
the first dose, and at weekly intervals. Data on demographic
characteristics, contact history with active TB disease, medical
history, and prior medications were collected. Body weight
and height were measured, physical examination was per-
formed, and vital signs, including blood pressure and heart
rate, were taken. Laboratory examinations including hema-
tology, blood chemistry, CRP, rheumatoid factor, HBsAg,
HCVantibody, urinalysis, and a pregnancy test in women were
performed during a fasting state. A complete joint assessment
(68-joint version) was performed for measurement of a tender
joint count (TJC), swollen joint count (SJC), and duration of
morning stiffness was recorded by an experienced rheuma-
tologist who was blinded to the results of other evaluations.
Each patient underwent chest X-ray and 12-lead electrocar-
diogram. Initially, all patients underwent a 4-week washoutFig. 1. Flow chart showing the enrolled patients with active rheumatoid arthritis (RA
three dose levels of TuNEX. This was an open-labeled, nonrandomized, sequential
study. CRP ¼ C-reactive protein; DLT ¼ dose-limiting toxicity; ESR ¼ erythrocyperiod prior to commencement of treatment with trial medi-
cations. After the washout period, baseline laboratory data
were checked to determine eligibility for participation.
In addition, all patients received baseline TB screening
using tuberculin skin test (TST) according to the Mantoux
method (intradermal injection of 2 tuberculin units of PPD
RT-23).14 The two-step TST was not performed in any of our
patients at baseline screening. The size of induration was
measured 48e72 hours later, and a positive result was defined
as the induration diameter 5 mm.15
3. Study objectives3.1. PrimaryThe primary objective of the study was to evaluate the
safety and tolerability of three fixed doses of TuNEX in
patients with RA. The occurrence of treatment-emergent
adverse events (TEAEs) was the primary safety variable.
The proportion of patients reporting DLT at each dose level
was the primary safety endpoint.3.2. SecondaryThe key secondary objective was to determine the most
effective dose of TuNEX in patients with RA according to the
ACR response criteria. In addition, immunogenicity of
TuNEX in patients with RA was also determined.
The proportions of patients with ACR20 and ACR50
response for each dose level were the efficacy endpoints of this
study. To avoid interobserver variability in the evaluation of
ACR response, there was only one well-trained rheumatologist
who examined the therapeutic responses for all enrolled) for this phase I/II clinical trial to assess the safety and preliminary efficacy of
dose escalating (TuNEX 15 mg, 25 mg, and then 35 mg twice weekly) clinical
te sedimentation rate; TST ¼ tuberculin skin test.
Table 1
Demographic and baseline characteristics of patients with rheumatoid arthritis
receiving different dose levels of TuNEX.
Characteristics TuNEX 15 mg TuNEX 25 mg TuNEX 35 mg
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response in a blind way with respect to the laboratory results.
Patients were assessed for the primary efficacy endpoint.
A patient was defined as “responder” in the ACR20
response at Week 4 in the modified full analysis set if the
following three criteria were met: a  20% improvement in
TJC; a  20% improvement in SJC; and a  20% improve-
ment in at least three of the following assessments: pain visual
analog scale (VAS, 0 being no pain and 100 being severe
pain); patient’s global assessment of disease activity (0 being
no disease activity and 10 being extreme disease activity);
physician’s global assessment of disease activity (0 being no
disease activity and 10 being extreme disease activity); the
disability index of HAQ (0 being without difficulty, 1 being
with some difficulty, 2 being with much difficulty, and 3 being
unable to do so), and CRP values. A patient was considered an
ACR 50% responder if there was at least 50% reduction of the
modified full analysis set at Week 4 from baseline.
Safety was evaluated by (1) proportion of patients reporting
DLT at each dose level. DLT was defined (according to
Common Terminology Criteria for Adverse Events, Version
3.0) as any treatment-related adverse event (AE)  grade 2 or
any AE  grade 3, (2) maximum tolerated dose (MTD), which
was defined as the maximal dose with less than one-third of
patients demonstrating DLT, (3) proportion of patients with
antibodies to TuNEX, (4) clinically significant changes in vital
signs, physical examination or laboratory parameters, and (5)
incidence of adverse events.
Auto-antibody tests [antinuclear antibodies (ANA), anti-
double-stranded-DNA (anti-dsDNA) Ab, anti-cardiolipin
Ab (ACA), anti-b2-glycoprotein I Ab (ABGI Ab), anti-
phosphatidylserine Ab (APTS Ab), lupus anticoagulant
(LAC) screening ratio] were performed at baseline before
TuNEX therapy and the end of therapy or upon early with-
drawal. Anti-TuNEX antibody was determined by enzyme-
linked immunosorbent assay.(n ¼ 6) (n ¼ 6) (n ¼ 6)
Age, yrs3.3. Statistical analysisMean (SD) 52.2 (10.16) 52.30 (8.32) 53.19 (8.57)
Sex
Women 6 (100%) 6 (100%) 6 (100%)
BMI, kg/m2
Mean (SD) 24.15 (2.45) 19.73 (2.14) 24.32 (4.06)
Tender joints
Median 7.50 8.00 22.50
IQR (4.97, 15.37) (5.26, 13.74) (9.53, 37.47)
Swollen joints
Median 6.00 8.00 15.50
IQR (4.12, 13.88) (5.87, 11.13) (9.88, 20.45)
ESR, mm/h
Median 45.00 37.50 57.50
IQR (25.59, 62.41) (16.05, 70.95) (34.48, 82.85)
CRP, mg/L
Median 0.96 2.17 1.49
IQR (0.17, 2.09) (0.54, 4.00) (0.42, 2.78)
BMI ¼ body mass index; CRP ¼ C-reactive protei; ESR ¼ erythrocyte
sedimentation rate; IQR ¼ interquartile range; SD ¼ standard deviation.The efficacy analysis was performed on an intent-to-treat
population, which was defined as all patients with baseline
data and at least one post-treatment evaluation. The last
observation carried forward method was used to substitute for
missing data. Primary and secondary efficacy variables were
analyzed by calculating the change and percentage change
from baseline at weeks 4, 8, and 12 (endpoint). The change
and percent change from baseline in the treatment group were
determined by nonparametric Wilcoxon signed rank test. The
differences between treatment groups for the efficacy
endpoints were compared by nonparametric Wilcoxon rank
sum test. The differences in the ACR 20% and 50% response
rate were analyzed by Fisher’s exact test.
The safety analysis was performed on all patients who
received randomized study medication. TEAEs included all
adverse events that either began on or after administration of
study drugs or pre-existing conditions that worsened on or
after study drug administration. The number and percentage ofsubjects reporting TEAEs were tabulated by MedDRA16
preferred terms and system organ class. Vital signs and labo-
ratory data profiles were analyzed based on change from
baseline using nonparametric Wilcoxon rank sum test for the
analysis between treatment groups and Wilcoxon signed rank
test for the analysis within treatment groups. The number of
patients with adverse events was compared between treatment
groups using Fisher’s exact test. Ordinal variables were
analyzed using the Cochran-Mantel-Haenszel test.
4. Results4.1. Demographics and baseline characteristicsIn this study, 18 patients were assigned to treatment, and
nine patients were not eligible after screening (ESR< 28 or
CRP < 2.0 mg/dL in three patients, positive results for TST in
three patients, and viral hepatitis in three patients). All patients
with RAwho received TuNEX treatment were women (100%)
with a mean age of 53.1 (range, 38.4e63.0 years). As illus-
trated in Table 1, there were no significant differences in
demographic data, baseline characteristics, including values
for body mass index, disease activity, disability index of the
HAQ, and baseline chemistry values among the three TuNEX-
treated groups.4.2. Efficacy assessment: ACR20 and ACR50 responseThe number of patients who discontinued treatment was
three (one patient in the TuNEX 25-mg group, two patients in
the TuNEX 35-mg group). Of these three patients, one patient
Fig. 2. The proportion of patients with rheumatoid arthritis who met the
American College of Rheumatology (ACR) criteria for (A) 20%; and (B) 50%
improvement (ACR20 and ACR50, respectively).
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discontinued after 2 days due to abnormal results of chest
X-ray screening (a nodular lesion 2.5  2.0 cm over the right
upper lung lobe), one patient in the 35-mg group received four
courses of TuNEX and discontinued due to the emergence of
maculopapular rashes over four extremities in moderate
degree, and the other patient in the 35-mg group received four
courses of TuNEX and discontinued due to misuse dosage.
Therefore, a total of 15 patients were evaluated for efficacy at
Week 4.
The primary efficacy endpoint with RA was the proportion
of patients with ACR20 at the end of treatment. As illustrated
in Table 2, more patients in the TuNEX 15-mg-treated group
achieved ACR20 and ACR50 responses compared with those
in the TuNEX 25-mg-treated group and TuNEX 35-mg-treated
group after 4 weeks of treatment, although these differences
were not statistically significant in this study. As shown in
Fig. 2A, the highest percentages of TuNEX 25-mg- and
35-mg-treated patients achieved an ACR20 response for the
first time at Week 2 during the 4-week treatment period. There
was a trend toward a superior ACR20 response rate in the
TuNEX 15-mg group (83.3%) in comparison with the TuNEX
25-mg group (40.0%) and TuNEX 35-mg group (50.0%) at
week 4. As shown in Fig. 2B, the highest percentages of
TuNEX 25-mg- and 35-mg-treated patients achieved an
ACR50 response for the first time at Week 3 during the 4-week
treatment period. No significant difference in the proportion
of patients who achieved ACR50 response after completion
of treatment was observed in the TuNEX 15-mg group
(33.3%) in comparison with the TuNEX 25-mg group (20.0%)
and TuNEX 35-mg group (25.0%). Individual measurement
of ACR items showed a marked improvement of all the
dimensions.
At baseline, higher values of ESR and CRP in the TuNEX-
25 mg group and TuNEX-35 mg group were observed inTable 2
Therapeutic response to TuNEX in patients with rheumatoid arthritis who







ACR20 at wk 4 5/6 (83.3%) 2/5 (40.0%) 2/4 (50.0%)
ACR50 at wk 4 2/6 (33.3%) 1/5 (20.0%) 1/4 (25.0%)
ESR reduction at wk 4 (%) 43.3% 11.1% 38.6%
CRP reduction at wk 4 (%) 68.1% 30.0% 85.0%
Daily steroid dose (mg) 8.3  2.0 6.3  3.1 7.5  2.2
Used DMARDs
Methotrexate 4 (66.7%) 4 (66.7%) 5 (83.3%)
Sulfasalazine 3 (50.0%) 4 (66.7%) 5 (83.3%)
Hydroxychloroquine 3 (50.0%) 4 (66.7%) 5 (83.3%)
Azathioprine 4 (66.7%) 1 (16.7%) 0 (0.0%)
Leflunomide 4 (66.7%) 5 (83.3%) 2 (33.3%)
Cyclosporine 0 (0.0%) 0 (0.0%) 1 (16.7%)
ACR20 ¼ 20% improvement based on American College of Rheumatology
(ACR) response criteria; ACR50 ¼ 50% improvement based on ACR response
criteria; CRP ¼ C-reactive protein; DMARDs ¼ disease-modifying anti-
rheumatic drugs; ESR: erythrocyte sedimentation rate.
a Data are presented as mean SD or number (percentage).comparison with the TuNEX-15 mg group. At follow-up of
TuNEX treatment, the mean values of ESR and CRP improved
after all three dosages of treatment. Patients who received
15 mg, 25 mg, and 35 mg had 43.3%, 11.1% and 38.6%
reductions in ESR, respectively, after the completion of
TuNEX treatment. Similarly, patients who received 15 mg,
25 mg, and 35 mg had 68.1%, 30.0%, and 85.0% reductions in
CRP levels, respectively, at the end of the therapeutic course
of TuNEX.
The HAQ is the most common assessment tool for func-
tional disability. In the present study, patients who received
15 mg TuNEX, 25 mg TuNEX, and 35 mg TuNEX had
35.99%, 16.85%, and 21.86% reductions of HAQ score after
drug treatment, respectively (Fig. 3). Our results indicate that
disability scores were improved in all TuNEX dosage groups.4.3. The occurrence of TEAEsThe safety population was defined as all eligible patients
who received at least one injection of TuNEX. All of the 18
eligible patients were included in the safety analysis (Table 3).
Fig. 3. Reduction of health assessment questionnaire (HAQ) disability score
was observed in all TuNEX dosage groups. W1 ¼ first week; W2 ¼ second
week; W3 ¼ third week; W4 ¼ fourth week.
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predominantly mild to moderate in intensity. The most
commonly reported TEAE in TuNEX-treated groups was
injection-site reaction with manifestation of mild urticaria,
erythema, and pruritus. The only DLT occurring in the study
was observed in the highest TuNEX dosage group. This
patient, a woman 38 years of age, developed maculopapular
rashes over four extremities and her trunk along with elevated
anti-dsDNA antibody after four injections of TuNEX. The
adverse reaction was resolved following discontinuation of
TuNEX. No other clinical signs of systemic lupus eryth-
ematosus (SLE) were found in this patient. This reported DLT,
with “moderate” severity, was judged by the investigators as
“highly probably related to study drugs.” However, TuNEX
treatment did not result in any severe adverse event or
occurrence of infections. No deaths or malignancies were re-
ported during the study.Table 3
Treatment-emergent adverse events observed in patients with rheumatoid arthritis
Characteristic TuNEX 15 mg
Patients with AE (no.) 2/6 (33.33%)
Patients with treatment-related AE (no.) 1/6 (16.67%)
Patients with SAE (no.) 0/6 (0.0%)
Patients with treatment-related SAE (no.) 0/6 (0.0%)
Patients who discontinued due to AE (no.) 0/6 (0.0%)
Patients who discontinued due to SAE (no.) 0/6 (0.0%)
Patients who died due to AE (no.)
Patients who died due to AE (no.) 0/6 (0.0%)
Adverse events (AEs)
Skin reaction 1/6 (16.7%)
Feature Urticaria
Severity Mild
Constipation (mild) 0/6 (0.0%)
Myofascial pain (mild) 1/6 (16.7%)
Treatment-related AE
Skin reaction 1/6 (16.7%)
Feature Urticaria
Severity Mild
AE ¼ adverse events; SAE ¼ serious adverse events.Evaluation of laboratory changes, including ANA and anti-
dsDNA antibodies, did not demonstrate any clinically relevant
differences among the three treatment groups. The presence of
antiphospholipid antibodies, including ACA (IgA, IgM, and
IgG), ABGI antibodies, or LAC after TuNEX treatment did
not reach a significant level in any patient with RA. One
patient in the TuNEX 35-mg-treated group had newly devel-
oped APTS antibodies (IgG and IgM) at low titers at the end of
the study, but these were not considered as clinically signifi-
cant. This suggests that the proposed maximum tolerated dose
(MTD) allows continuous treatment over 4 weeks. In addition,
none of patients receiving any of the three dose levels of
TuNEX in the present study developed a positive anti-TuNEX
antibody during the 4-week treatment and 2-week follow-up
period.
5. Discussion
The present study combined the objectives of phase I and II
to provide some evidence that TuNEX can be tolerated by
Taiwanese patients with RA. Therefore, an open-label, non-
comparative study design was considered to obtain safety data.
This was a noncomparative study; therefore, neither random-
ization nor a control group was used. Our results showed that
TuNEX could reduce the signs and symptoms of active RA
and improve physical function, with a clinically acceptable
safety and tolerability profile in patients who had previously
received DMARDs.
TuNEX (a recombinant TNF receptor protein) acts by
binding TNF-a, which plays a pivotal role in the pathogenesis
of RA.4e6 Consistent with previous clinical trials,7e10 the
present study showed that TuNEX alone in three different
doses was well tolerated and provided clinical efficacy in
Taiwanese patients with RA. During the 4-week treatment
period, signs and symptoms of RA were relieved as early asreceiving different dose levels of TuNEX.
TuNEX 25 mg TuNEX 35 mg
2/6 (33.33%) 2/6 (33.33%)
2/6 (33.33%) 1/6 (16.67%)
0/6 (0.0%) 0/6 (0.0%)
0/6 (0.0%) 0/6 (0.0%)
0/6 (0.0%) 1/6 (16.7%)
0/6 (0.0%) 0/6 (0.0%)
0/6 (0.0%) 0/6 (0.0%)
2/6 (33.3%) 1/6 (16.7%)
Erythema, pruritus Maculopapular rash
Mild Moderate
0/6 (0.0%) 1/6 (16.7%)
0/6 (0.0%) 0/6 (0.0%)
2/6 (33.3%) 1/6 (16.7%)
Erythema, pruritis Maculopapular rash
Mild Moderate
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mg-treated patients achieved an ACR20 response for the first
time at Week 2. More patients in the TuNEX 15-mg-treated
group achieved ACR20 and ACR50 responses compared with
those in the TuNEX 25-mg-treated group and TuNEX 35-mg-
treated group after 4 weeks of treatment, although these
differences were not statistically significant in this exploratory
study. Our results are much different from the findings of
previous studies showing a dose-dependent response to TNF-
a inhibitors in patients with RA or psoriasis.17,18 This
discrepancy may be explained by dissimilar disease activities
at baseline, different proportions of patients treated with
DMARDs among the three dose groups, a small number of
enrolled patients, short duration of treatment, and individual
differences in response to treatment in our study. Moreover,
the ACR response criteria are only a relative measure and not
necessarily a realistic tool for the definition of therapeutic
success.19 Larger and longer phase III study using additional
response criteria, such as the European League Against
Rheumatism response criteria,20 to demonstrate the efficacy of
TuNEX in patients with RA will be needed in the future. In
addition, the ACR20 response rate of TuNEX 35 mg-treated
patients was lower in the present study than the rate observed
in previous studies using similar biologics.7,8 This disparity
may be due to the differences in the sample size, the baseline
characteristics, the used concomitant therapy (without versus
with methotrexate), the biologic agents, and the duration of
antieTNF-a therapy.
The time courses of clinical response are different among
the three dose-level groups: both the TuNEX 25 mg and 35 mg
groups showed a decrement in clinical response between the
second and third weeks, but the 15-mg group did not (Fig. 2).
Although the development of antibodies against TNF-a
blockade may occur in dose- or duration-dependent manner
and affect the clinical response,21,22 none of our patients
receiving any of the three dose levels of TuNEX developed
a positive anti-TuNEX antibody during the 4-week treatment.
In view of the short duration of treatment, a longer phase III
study will be required to clarify the association of immuno-
genicity with clinical response.
The HAQ, the most common assessment tool for functional
disability, is a 20-item questionnaire for which scores range
from 0 to 3. Wolfe and colleagues23 reexamined the hypothesis
and showed that the HAQ disability index is a good model of
disability, using data from a large, prospective, long-term
study of disability in RA. As shown in Fig. 3, our results
indicate that disability scores improved in all TuNEX dosage
groups.
In the present study, there were no differences in the inci-
dence of adverse events among the three dose levels of
TuNEX-treated groups. The most commonly reported TEAE
was injection-site reactions with a median duration of 3 days.
Our results were similar to the findings of previous clinical
trials with sc TNF-a inhibitors showing that the occurrence
rate of injection-site reactions from 10.6% to 37.0%.24,25
Maculopapular rash over four extremities and trunk was the
only DLT that required interruption of treatment in onepatient; she was treated with highest dose of TuNEX. There-
fore, maximum tolerated dose MTD was presumably higher
than 35 mg of TuMEX.
Induction of autoantibodies is a predictable consequence of
TNF-a inhibitors,26e28 which could (1) promote humoral
autoimmunity by inhibiting cytotoxic T-lymphocyte response
that normally suppresses autoreactive B cells, and (2) enhance
apoptotic processes that increase the release intracellular
autoantigens and then development of autoantibodies against
nuclear and cytoplasmic components.26 In the present study,
the emergence of newly developed ANA, anti-dsDNA, and
APTS antibodies was mainly observed in the highest TuNEX
dosage group. Our results were consistent with the findings of
previous studies showing that the prevalence of ANA induc-
tion ranges from 23% to 57%, and the prevalence of anti-
dsDNA antibody induction ranges from 9% to 33% in
patients receiving anti-TNF-a therapy.27 Although none of our
patients developed signs/symptoms of lupus-like syndrome or
specific autoimmune disease, one patient developed mac-
ulopapular rashes along with elevated anti-dsDNA antibody
after TuNEX treatment, and resolution of lesions followed
withdrawal of this agent. Our finding was similar to the results
of a systemic review showing that cutaneous involvement as
well as anti-dsDNA antibodies is more common in anti-
TNFeinduced lupus compared to classical drug-induced
lupus.28 No evidence has been shown to support a positive
relationship between the presence of autoantibodies and RA
improvement by TuNEX treatment. In the present study, the
duration of treatment was too short to draw a definitive
conclusion regarding safety profile. Although preclinical
pharmacology and toxicology (phase I) studies have been
conducted to demonstrate the safety of TuNEX, longer phase
III study to demonstrate the safety of TuNEX in patients with
RA will be needed.
In conclusion, three dose levels of TuNEX were effective in
the treatment of RA with clinical and functional improvement
during the 4-week treatment period. Considering the adverse
event and severe adverse event incidences and premature
discontinuation, TuNEX was shown to have clinically
acceptable safety and tolerability profile over a period of 4
weeks. This favorable safety profile of TuNEX clearly implies
an improved adherence to therapy. This study has demon-
strated that treatment of Taiwanese patients who have RAwith
TuNEX has a favorable benefit-risk ratio. In light of the small
number of enrolled patients and short duration of treatment in
our study, the favorable benefit/risk relationship of TuNEX
warrant a larger and longer phase III study to demonstrate the
efficacy and safety of TuNEX in Chinese patients with RA.
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